We conducted a systematic review and meta-analysis to estimate the potential association between LCv-3PUFAs and prostate cancer (PC). A comprehensive literature search was performed through 2013 to identify prospective studies that examined dietary intakes of long-chain omega-3 polyunsaturated fatty acids (LCv-3PUFA) or blood biomarkers of LCv-3PUFA status and risk of PC. Random-effects meta-analyses were conducted to generate summary relative risk estimates (SRREs) for LCv-3PUFAs and total PC, and by stage and grade. Subgroup analyses were also conducted for specific fatty acids and other study characteristics. Twelve self-reported dietary intake and 9 biomarker studies from independent study populations were included in the analysis, with 446,243 and 14,897 total participants, respectively. No association between LCv-3PUFAs and total PC was observed (SRRE D 1.00, 95% CI: 0.93-1.09) for the dietary intake studies (high vs. low LCv3PUFAs category comparison) or for the biomarker studies (SRRE of 1.07, 95% CI: 0.94-1.20). In general, most summary associations for the dietary intake studies were in the inverse direction, whereas the majority of summary associations for the biomarker studies were in the positive direction, but all were weak in magnitude. The results from this meta-analysis do not support an association between LCv-3PUFAs and PC.
INTRODUCTION
Prostate cancer (PC) is the most common cancer among men in the United States, with 233,000 incident cases and 29,480 deaths estimated for 2014 (1, 2) . PC is the second-leading cause of malignant death in U.S. men, behind lung cancer. The etiology of PC is largely unknown, although older age, African American race, family history of PC, and genetic variations and mutations have been shown to be associated with the disease (1, 2) . Potential modifiable risk factors, such as obesity, lack of exercise, and smoking, have been linked with risk of PC; however, the magnitude of these factors on PC risk has yet to be established (3) (4) (5) (6) . Despite the abundance of epidemiologic studies examining the role of diet and dietary/ nutrition/food supplements on PC risk, no dietary risk factor has shown any clear associations with this malignancy (6) .
Animal and in vitro experimental studies have indicated that LCv-3PUFAs may inhibit carcinogenesis (15) . One hypothesis for these results is that LCv-3PUFAs may reduce inflammation given that regions of proliferative inflammatory atrophy in prostate epithelial cells may be etiologically important (12, 13) . Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) omega-3 fatty acids, for example, may reduce inflammation via both by the displacement of arachidonic acid (ARA) in membrane phospholipids, which can reduce the production of some proinflammatory signaling molecules (7, 8) , and by the direct production of antiinflammatory or proresolution mediators from EPA and DHA (9) (10) (11) .
Epidemiological studies of a possible relationship between LCv-3PUFA intake and PC have been mixed. Relative risks (RRs) above and below the null value have been reported across the prospective cohort studies. Most dietary intake studies reported RRs below 1.0, whereas most biomarker studies reported RRs above 1.0. However, results within these groups have been variable by exposure factors and outcome factors, such as specific LCv-3PUFA and tumor histology.
Findings from 2 recent meta-analyses (16, 17) were not consistent with the hypothesis that LCv-3PUFAs had anticarcinogenic activity; indeed, both reported some positive associations between LCv-3PUFA levels and risk for highgrade PC. Although Chua et al. (17) reported nonsignificant inverse findings between individual LCv-3PUFAs and total and advanced PC, the authors found a significant positive association between DHA and EPA (combined as one exposure variable) and high-grade prostate cancer. Brasky et al. (16) reported a statistically significant positive association between total LCv-3PUFAs and high grade PC, and positive results for total, low-grade, and high-grade PC for EPA (nonsignificant) and DHA (significant) in their meta-analysis. These 2 metaanalyses only examined biomarker studies and did not evaluate studies based on dietary LCv-3PUFAs intakes. Together both types of exposure measurements would allow for a more complete understanding of the potential relationship between LCv-3PUFAs and PC.
In light of the mixed results from epidemiological studies and meta-analyses, we conducted a meta-analysis using data from both LCv-3PUFA dietary intake studies and LCv3PUFAs biomarker studies, data from recently published prospective studies (that were not included in previous meta-analyses), and data obtained from direct correspondence with authors. The primary objective was to estimate summary associations for high LCv-3PUFAs categories compared with low categories (separately for dietary intake and biomarker studies). Secondary aims were to (a) examine potential sources of statistical heterogeneity among subgroup stratifications, such as specific fatty acids and PC stage and grade; (b) conduct sensitivity analyses based on individual study influence and other study parameters; (c) estimate the relative influence of each study to the overall estimate; (d) examine dose-response patterns on a study-by-study basis; and (e) evaluate the potential for publication bias.
METHODS

Literature Search and Study Inclusion
A systematic literature search, following guidelines discussed in the scientific literature (18, 19) (6) , and the FAO/WHO joint expert consultation (20) . However, no additional studies were identified based on the supplemental literature searches.
The review was conducted in accordance with established guidelines for systematic reviews specific to human intervention studies in nutritional science (64) . Eligible study designs were prospective studies (including cohorts and randomized controlled trials) published in English language that reported quantitative data for LCv-3PUFAs (dietary intake, supplemental intake, or biomarker status). Consistent with the available literature, LCv-3PUFAs included EPA, DHA, and docosapentaenoic acid (DPA) as reported in the individual studies. The outcomes of interest were incident and fatal PC, which included specific subtypes such as nonadvanced/advanced, metastatic, and low/high grade PC. Although studies may differ slightly in diagnostic vernacular, PC is generally defined as 544 D. D. ALEXANDER ET AL.
"advanced" when it spreads outside the prostate gland to nearby tissues, and "metastatic" when it spreads beyond tissues directly adjacent to the prostate gland. PC grade refers to the tumor's appearance and indicates the rapidity of malignant growth.
Study populations included free-living adults, and studies were required to report RRs with 95% confidence intervals (CIs). We excluded editorials, abstracts, case-control studies, cross-sectional studies, case reports or series, and animal or in vitro studies. Studies that reported only total seafood or fish intake and did not provide quantitative estimates of LCv3PUFAs were also excluded.
Of the original 313 references identified in the literature search, 254 were excluded based on initial screening. Twentytwo review articles were retained for examination of reference lists, and thirty-seven articles-all of which were observational studies-underwent full-text review. One randomized controlled clinical trial of LCv-3PUFAs and cardiovascular events after myocardial infarction was identified (21) for which PC incidence was listed in the supplementary material. This article was retrieved but not included in our quantitative assessment because PC occurrence was reported as a possible adverse event and limited data on this outcome were available. Based on full-text review and applying the above inclusion and exclusion criteria, a total of 21 prospective cohort studies published in the English-language were included in this analysis.
Data Extraction and Statistical Analysis
We extracted qualitative and quantitative information from each study, including author and year of study, geographic study location, the name of the cohort (if applicable), study size, years of follow-up, type of exposure, method of exposure assessment (i.e., dietary intake, biomarker), exposure metric units, analytical comparisons, number of exposed cases, RR estimates for overall outcome measures as well as subgroup comparisons, 95% CIs, and the variables that were statistically adjusted for or were matched on for each respective RR estimate.
Studies provided the median intake or biomarker levels for each quantile (dietary intake category or biomarker status category expressed as tertiles, quartiles, or quintiles) and an associated RR. Although all studies reported risk estimates for total PC, not all reported data for specific types of PC, such as grade. Thus, we contacted authors from the most recent publications to request estimates for these specific outcomes. We were able to obtain additional risk estimates on tumor grade and stage from Bassett et al. (14) and Park et al. (22) . Statistical analyses were based on comparisons of the highest exposure category with the lowest. In addition, we reviewed doseresponse patterns on a study-by-study basis to see if trends were apparent (i.e., a monotonic increase in risk based on increasing exposure). We did not combine such data in a categorical dose-response meta-analysis because of the variability of exposure categories.
Random-effects models were used to calculate summary RR estimates (SRREs), 95% CIs, and corresponding P values for heterogeneity. The primary meta-analysis models consisted of combined data from all studies (EPA, DHA, and DPA combined, and total PC). For example, if EPA and DHA were reported separately for the same study (total not reported), data for each category were combined in a fixed effects model to produce a single estimate. This estimate was then used in a random effects meta-analysis model with all other studies. Separate subgroup models by tumor stage and grade, specific fatty acid, and other study characteristics were generated. The relative influence of each study on the overall risk estimate was determined in sensitivity analyses (i.e., each individual study was removed and the summary estimate with and without the study was evaluated to determine the sensitivity of the model based on study inclusion/exclusion). If data for specific PC outcomes, such as nonadvanced and advanced but not total PC were reported, each point estimate and CI was included in the model as these were considered mutually exclusive cases. Statistical heterogeneity was assessed using the Cochran's Q test and I 2 statistic. The presence of publication bias was assessed visually by examining a funnel plot measuring the standard error as a function of effect size, as well as performing Egger's regression method and the Duval and Tweedie imputation method (23) . All statistical analyses were performed using the Comprehensive Meta-Analysis statistical software package (24) .
RESULTS
The primary study characteristics of the 21 prospective cohorts are shown in Table 1 . A total of 446,243 participants were included in the meta-analysis of dietary intake studies and 14,807 in the meta-analysis of biomarker studies; 1 cohort (14) examined both biomarkers and self-reported dietary intakes and was included in both analyses. Two studies (25, 27) reported specifically on PC mortality. Follow-up ranged from 1.9 yr (22) to 20 yr (26, 27) . The majority of dietary intake studies assessed diet using food-frequency questionnaires, whereas most biomarker studies examined serum or plasma phospholipid levels. Twelve cohorts were in the United States or Canada, 8 were in Europe, and 1 was in Australia. The meta-analysis results are summarized in Table 2 (based on high vs. low intake or biomarker level).
Dietary Intake of LCv-3PUFAs
No association was observed in the meta-analysis of 12 studies that reported data for dietary intake of LCv-3PUFAs and total PC (SRRE D 1.00, 95% CI: 0.93-1.09) ( Table 2 (14) observed nonsignificant decreased risks for total PC and EPA, DHA, and DPA. Analyzing a 1% unit increase in energy from fish fat, Crowe et al. (32) reported no associations for total, nonadvanced, advanced, low-grade, and high-grade PC. Epstein et al. (27) reported no significant associations for fatty acids and total, nonadvanced, or advanced PC, although most RRs were below unity. Schuurman et al. (33) reported no significant associations for EPA or DHA and PC.
Some studies did not analyze continuous data to generate risk estimates based on dose-response units. For these studies, we reviewed the RRs based on each increasing category of exposure to determine if a dose-response trend was apparent (i.e., a monotonic increase in risk based on increasing exposure). 
Biomarkers of LCv-3PUFAs
A nonsignificant SRRE was observed in the meta-analysis of 9 biomarker studies of LCv-3PUFAs (SRRE D 1.07, 95% CI: 0.94-1.20; p-H D 0.065) (Table 2, Fig. 2) . A 1-studyremoved meta-analysis was conducted to evaluate the relative influence that each study had on the overall model. Removal of each study had a negligible impact on the overall summary effect; however, removal of Chavarro et al. (39) resulted in a statistically significant SRRE of 1.11 (95% CI: 1.01-1.21). Visual inspection of funnel plots and Egger's regression method and the Duval and Tweedie imputation method did not indicate the presence of publication bias. No differences in summary associations were observed after stratifying by study country (Table 2) .
There was some evidence of effect modification by biomarker status period and duration of follow-up, with nonsignificant inverse risk estimates among studies with initial assessments before 1990 and among studies with 10 or more years of follow-up compared with a significant positive association among studies with initial assessment after 1990 (SRRE Nonsignificant inverse SRREs were observed for LCv3PUFAs biomarkers and nonadvanced and advanced PC, although only 3 data points were analyzed for each model whereas nonsignificant positive SRREs were found for both low and high-grade PC (Table 2, Fig. 3) .
Analyses of EPA and DHA separately and total PC, produced similar nonsignificant positive SRREs. Half of the point estimates from the individual studies for DHA were in the inverse direction, whereas individual point estimates for EPA, except for 1, were in the positive direction. However, removal of Chavarro et al. (39) (the single study showing a decreased risk for EPA) did not affect the summary association. A significant inverse summary association between DPA and total PC was observed (SRRE D 0.85, 95% CI: 0.72-0.99) with no statistical heterogeneity.
Similar to the dietary intake studies, no consistent doseresponse relationships were evident in the biomarker studies. Two studies analyzed dose-response relationships using continuous data analysis. reported significant positive associations for LCv-3PUFAs and high-grade PC (RR D 1.99), DHA and high-grade PC (RR D 2.50), and DHA and total PC (RR D 1.22, data available for highest category only) in their highest exposure categories. However, RRs were stronger in magnitude for the lowest categories of exposure (RR for LCv-3PUFAs and high-grade PC D 2.15; RR for DHA and high-grade PC D 2.65), and thus, clear dose-response relationships are not supported. There was no consistent evidence for a dose-response relationship in the remaining six biomarker studies (22, 26, 38, 39, 41, 42) , with most RRs close to the null value and not statistically significant at the upper end of exposure, and many RRs in the lower categories of exposure were stronger in magnitude than the RRs in the higher categories of exposure.
DISCUSSION
This meta-analysis does not support an association between LCv-3PUFAs and PC risk. This is the first quantitative assessment to examine dietary intakes of LCv-3PUFAs as well as biomarkers of LCv-3PUFAs in relation to PC. For both analyses, summary results were weak in magnitude and generally close to null. Very few meta-analysis models produced statistically significant associations, and heterogeneity was present in many models. Such statistical heterogeneity would be expected in the absence of a clear and independent relationship between LCv-3PUFAs and PC risk, because RRs from individual studies would likely be in the vicinity of 1.0, on both sides of the null value. This is indeed the case in the dietary intake studies, with 6 point estimates below the null value for total PC, and 7 point estimates above it (Fig. 1) . Similarly, statistical heterogeneity was apparent in many of the biomarker studies, and this variation was partially explained by differences in the exposure ascertainment period and the duration of follow-up. For an outcome such as PC, which has a relatively long latency period (43), a longer follow-up time would be more appropriate to capture a true association, if the exposure was causally related to risk of disease. However, summary associations were in the inverse direction for the studies that followed participants for more than 10 yr and/or among studies with an initial dietary assessment period prior to 1990. In contrast, summary associations were in the positive direction for studies with a follow-up period less than 10 yr and/or among studies with initial dietary assessment periods in 1990 or later.
An overall lack of consistency is apparent in the summary results across the various models ( Table 2 ). The most striking observation is that most summary associations are in the inverse direction in the analyses of the dietary intake studies of LCv-3PUFAs, and most, but not all, summary associations are in the positive direction for the biomarker studies. Each method of estimating exposure to LCv-3PUFAs is informative, with important advantages and limitations; thus, both types of studies should be appraised critically when reviewing evidence on LCv-3PUFAs and PC risk. The most frequently used self-report diet assessment tool among the individual studies included in this meta-analysis was the food frequency questionnaire. This tool captures intakes of foods, beverages, and, in some cases, dietary supplements, consumed by individuals over a specified reference period (often 1 yr). However, diet is measured with error, which can be random or systematic (44) . Such exposure misclassification could bias results in either direction. This measurement error has led some researchers to investigate theoretically more objective measures of LCv-3PUFA intake, namely, biomarkers, including fatty acid levels in plasma/serum phospholipids, whole blood, cholesterol esters, or red blood cell (RBC) membranes. Compared with intakes estimated from self-report methods, these biochemical markers could provide a more accurate estimate of exposure without the potential for self-reporting bias (45) . Indeed, the LCv-3PUFA content of RBCs (46) (47) (48) (49) (50) (51) and of phospholipids (52, 53) are both validated biomarkers of intake. However, such measurement methods are not without limitations. Many of the serum/plasma-based biomarkers used in the individual studies included in this meta-analysis reflect relatively recent intake (past 1 to 2 days) and display fairly high intraindividual variability (55) . RBC membranes, on the other hand, reflect intakes of approximately one month (54) and are less variable day to day (55) . Another key consideration favoring the use of biomarkers as measures of exposure is that LCv-3PUFA blood concentrations are not solely from marine sources, as a small proportion is derived from the conversion of plant-derived alpha-linolenic acid to LCv-3PUFA, which can vary from person to person (49) .
Recent meta-analyses of epidemiologic studies have examined the relationship between LCv-3PUFAs and PC (16, 17, 56, 57) , with mixed conclusions. Differences in these meta-analyses likely contributed to the discrepant findings. These differences include the use of fixed-effects models (accounts for within-study variation) (16) vs. the more appropriate random-effects models (accounts for both, within, and between-study variation) (17, 56, 57) , and differences in the types of study designs included. Chua et al. (56) reported associations close to the null value between higher self-reported dietary intakes of total LCv-3PUFAs, as well as EPA and DHA separately, and total PC incidence. In a separate metaanalysis of biomarker studies, Chua et al. (17) reported nonsignificant associations between higher vs. lower blood levels of individual EPA, DHA, and DPA and total PC incidence. In a subgroup analysis of studies that examined high-grade PC, nonstatistically significant positive findings were observed (17) . Summary associations between total LCv-3PUFAs levels, as well as individual EPA and DHA levels, and total PC from a meta-analysis of biomarker studies (57) were close to the null value, but a statistically significant reduced risk for total PC was reported for higher DPA levels. This latter finding remained significant in a meta-analysis that removed the META-ANALYSIS OF LCv-3PUFA AND PROSTATE CANCER retrospective case-control studies (57). Brasky et al. (16) , using a fixed effects meta-analysis model, examined prospective nested case-control and case-cohort studies. Among the 9 summary associations from stratified analyses by fatty acid (EPA, DHA, and total LCv-3PUFAs) and grade of PC (total, low-grade, and high-grade), 4 were significantly positive. Brasky et al. (40) reported inverse associations with plasma phospholipid trans-fatty acid levels and high-grade PC risk, which is inconsistent given that trans-fatty acids have been linked with higher inflammatory status (58) .
Our methodological protocol for the biomarker studies analysis is similar to the one used by Brasky et al. (16) in that we included only studies with prospective designs. However, we also included dietary intake studies, as was done by Chua et al. (56) . Our summary associations in the analysis of biomarker studies are closer to the null value compared with those reported by Brasky et al. (16) [Summary RR comparing highest to lowest level of blood LCn3PUFA: 1.51 (95% CI: 1.08, 2.11)]. This discrepancy might be attributable to the inclusion of data from 2 recently published studies (14, 26) in this metaanalysis but not included by Brasky et al. (16) , a larger number of subgroup and sensitivity analyses, and utilization of random-effects meta-analysis models that take into account both within-and between-study variability. As indicated, we conducted numerous subgroup and sensitivity analyses to examine consistency of findings across different models with the expectation that summary associations would be consistently elevated if LCv-3PUFAs were associated with increasing the risk of PC. If a true independent association were to exist, it would be expected that associations would be relatively strong in magnitude and that there would be a dose-response relationship. Moreover, it would be expected that summary associations by various methodological designs would substantiate each other. None of these situations have been satisfied: Summary associations are close to the null value and above and below 1.0, evidence of a dose-response relationship across the individual studies is lacking, and findings are inconsistent.
There is biological evidence supporting a role for LCv3PUFAs in the inhibition of prostate carcinogenesis (15, 26) . LCv-3PUFAs may inhibit prostate cell growth, and they may also have antiinflammatory, antiproliferative, and proapoptotic effects on PC cells (15, 26, 59 ). In contrast, there are few hypothesized mechanisms for which LCv-3PUFAs may contribute to prostate carcinogenesis. In the aforementioned analysis by Brasky et al. (16) , the authors note the beneficial physiological effects of LCv-3PUFAs, and they stated that it was unclear as to why LCv-3PUFAs could increase PC risk. Chua et al. (17) suggested that modifications in the androgen milieu from dietary fat intake may contribute to PC, and that the positive association observed for high-grade tumors may be due to a biochemical process in the prostate tissue. He et al. (60) and Azordegan et al. (61) both provide evidence that carcinogenesis (breast, lung) itself alters tissue fatty acid metabolism (e.g., increases in the activity of delta-6-desaturase). This could increase tissue (and possibly plasma) levels of LCv3PUFAs. This would be an example of reverse causation, where the disease caused the change in biomarker. Because in Brasky et al. (16) a much larger proportion of men who ultimately developed PC (30-40%) had PSA levels >3 at baseline (compared to 7% of the controls), it is possible that subclinical PC was already developing in the higher risk men, and differences in tissue biology, not fish intake or fish oil supplement use were responsible for the observed associations between incident PC and plasma phospholipid LCv-3PUFA levels.
Cheng et al. (26) indicated that the multiple double bonds in LCv-3PUFAs may attract reactive oxygen species or free radicals, which may lead to membrane and DNA damage that foster cancer development (62) . Further, Chua et al. (17) opined that an association may be apparent for high-grade tumors rather than for total or indolent PC because PSA screening may detect these tumors at an earlier stage (63) . Despite these hypotheses, findings from both the dietary intake and the biomarker status studies do not support a clear or consistent association between LCv-3PUFA biomarker levels and incident PC.
In summary, our meta-analysis of the published studies to date does not support an association between LCv-3PUFAs and the risk of PC. Analysis of dietary intake studies shows no overall association, and some models indicate small inverse associations. The majority of the biomarker studies showed slight positive and nonstatistically significant findings, but some summary associations were in the inverse direction. Importantly, weakly positive associations were produced by studies that used shorter follow-up periods, whereas analyses of the studies with follow-up periods more representative of the long latency period for PC tended to exhibit no or slightly inverse associations, an effect that was consistent in both dietary intake and biomarker studies. Finally, a plausible biological mechanism by which LCv-3PUFAs could facilitate prostate carcinogenesis has not been identified whereas antiinflammatory properties of these fatty acids would suggest anticarcinogenic effects. For all these reasons, any posited association between LCv-3PUFAs and PC, either positive or negative, is not supported by current epidemiologic evidence.
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